Cogent Biosciences Stock Soars on Promising Bezuclastinib Trial Results
Bezuclastinib shows promising results in treating systemic mastocytosis (SM), significantly improving symptoms and quality of life for patients in clinical trials. The drug reduced symptom severity by 56% and improved quality of life by 49% at 24 weeks.
Cogent Biosciences Stock Soars on Promising Bezuclastinib Trial Results Read More »